Biogen (BIIB) has shown strong growth in Q3 2025, beating profit expectations and expanding its portfolio through strategic moves such as the completion of the Alcyone deal. The pharmaceutical company plans to launch ThecaFlex DRx for SPINRAZA by 2028. Investors expect new drug sales to drive future growth, especially after BIIB gained approval for LEQEMBI maintenance dosing in the UK. Biogen's quarterly results along with increased R&D spending have significantly changed its investment story. Despite a one-time $471M loss, the company's valuation remains in focus as it continuously expands its neurology pipeline and secures new partnerships. BIIB's stocks have shown fluctuation; However, analysts have a positive outlook due to recent pipeline developments and apparent undervaluation of shares. BIIB has also successfully licensed Vanqua Bio's immune disorder drug for up to $1.06 billion and has announced a partnership with Eisai for LEQEMBI subcutaneous injection maintenance doses for early Alzheimer's treatment.
Biogen BIIB News Analytics from Wed, 02 Apr 2025 07:00:00 GMT to Sat, 15 Nov 2025 07:51:09 GMT -
